Favorable response to maintenance therapy of second or subsequent remissions in childhood acute lymphocytic leukemia

Jim C. Kimball, Jay Herson, Margaret P. Sullivan

Research output: Contribution to journalArticle

Abstract

Twenty‐two children with acute lymphocytic leukemia (ALL) who had relapsed while on therapy and for whom remissions were successfully reinduced were maintained with a combination of methotrexate, daunomycin, 6‐mercaptopurine, prednisone, and vincristine (Djerassi‐methotrexate with BOMB). The median duration of remission was 35 weeks (range, five to 364+ weeks). Of 8 children (36%) did not relapse while receiving this therapy, 4 are off all therapy (durations of remission, 40+, 97+, 132+, and 216+ weeks). Improved responses were found in children with platelet counts of greater than 105/mm3 at the time of index relapse. Intrathecal chemotherapy seemed to greatly prolong the duration of remission for 16 children when compared to those children who did not receive IT therapy (45.5 vs. 24 weeks). No central nervous system relapses occurred. This maintenance regimen for children with previously relapsed ALL appears to be effective and worth additional clinical trials.

Original languageEnglish (US)
Pages (from-to)1093-1097
Number of pages5
JournalCancer
Volume46
Issue number5
DOIs
StatePublished - Sep 1 1980
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Favorable response to maintenance therapy of second or subsequent remissions in childhood acute lymphocytic leukemia'. Together they form a unique fingerprint.

  • Cite this